
Adrian Radocea
@adrian_radocea
Bringing to market microgravity-enabled products as Chief Science Officer at Varda Space
ID: 818484861597925376
http://varda.com 09-01-2017 15:49:32
44 Tweet
109 Takipçi
109 Takip Edilen



The Varda team will be at #BIO2024 next week! Send us a note at [email protected] if you want to connect, or catch our talk at 4:15 on Monday! convention.bio.org/sessions/varda…



Varda is pioneering LEO biomedical research with our partners ISS National Lab toward a future where human-rated stations and autonomous platforms work together to benefit everyone. Our CSO Adrian Radocea will join International Space Station Chief Scientist Jennifer Buchli and ISSNL Chief

The House Science Committee committee has reauthorized NASA. We are grateful for the leadership of chairman Frank Lucas, subcommittee chairman Brian Babin, ranking members Congressman Eric Sorensen and Rep. Zoe Lofgren, and members of the committee who recognize the importance of

It was a pleasure to present at this year's ISSRDC. Michael Roberts and Jennifer Buchli ISS National Lab, thanks for having me! High-cadence access to microgravity is finally here, and at Varda Space Industries we're going even faster through hypergravity studies right here on Earth.






We successfully acquired signal from W-3. Our system health checks are now complete and we can confirm that the capsule is operating nominally. We'll see you again down under soon, Southern Launch Australian Space Agency!

Why the future of pharma is off-planet Varda Space Industries Will Bruey 00:00 A live conversation with Will Bruey 02:20 The Varda future 06:19 A history of human space travel 08:27 Drug development in space 11:33 The Varda culture 17:26 Retrieving from orbit 20:08 The Varda capsule 24:05



Another capsule has returned from space to regional South Australia – growing Australia’s reputation as a reliable spaceflight hub. Varda Space Industries successfully returned its Winnebago-3 (W-3) capsule to Southern Launch Koonibba Test Range in South Australia on Wednesday.



Today we’re announcing two pieces of news: 1) We raised $187 million Series C led by Natural Capital and Shrug Capital. 2) We’re expanding into a new lab space to begin work on biologics. Soon, space reentry will be ordinary and drugs made in orbit will be part of everyday care.
